229 related articles for article (PubMed ID: 8372486)
1. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
Kreipe HH
Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
[TBL] [Abstract][Full Text] [Related]
2. DNA analysis to aid in the diagnosis of chronic myeloproliferative disorders.
Kreipe H; Felgner J; Jaquet K; Heidorn K; Radzun HJ; Parwaresch R
Am J Clin Pathol; 1992 Jul; 98(1):46-54. PubMed ID: 1615925
[TBL] [Abstract][Full Text] [Related]
3. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
4. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
5. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
6. Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing the histologic classification of chronic myeloproliferative disorders.
Werner M; Nolte M; Kaloutsi V; Buhr T; Kausche F; Georgii A
Lab Invest; 1995 Apr; 72(4):405-10. PubMed ID: 7723278
[TBL] [Abstract][Full Text] [Related]
7. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
9. [Clonality and stem cell defects in the molecular pathology of chronic myeloproliferative disorders].
Kreipe H; Radzun HJ; Bartels H; von Heyden HW; Löffler H; Parwaresch MR
Verh Dtsch Ges Pathol; 1990; 74():49-64. PubMed ID: 1708635
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
Hyun BH; Gulati GL; Ashton JK
Clin Lab Med; 1990 Dec; 10(4):825-38. PubMed ID: 2272176
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
Rudzki Z; Papla B; Stachura J
Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
[TBL] [Abstract][Full Text] [Related]
13. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.
Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H
Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337
[TBL] [Abstract][Full Text] [Related]
15. Single chromosomal abnormalities in Philadelphia-negative chronic myeloproliferative disorders.
Panani AD
In Vivo; 2007; 21(5):867-70. PubMed ID: 18019426
[TBL] [Abstract][Full Text] [Related]
16. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Bacher U; Haferlach T; Kern W; Hiddemann W; Schnittger S; Schoch C
Ann Hematol; 2005 Apr; 84(4):250-7. PubMed ID: 15692838
[TBL] [Abstract][Full Text] [Related]
17. Evidence from molecular genetic and cytogenetic analyses that bone marrow histopathology is reliable in the diagnosis of chronic myeloproliferative disorders.
Werner M; Kaloutsi V; Kausche F; Buhr T; Georgii A
Virchows Arch B Cell Pathol Incl Mol Pathol; 1993; 63(4):199-204. PubMed ID: 8099457
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloproliferative disorders (CMPD).
Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
Pathol Res Pract; 1984 Nov; 179(2):131-86. PubMed ID: 6395125
[TBL] [Abstract][Full Text] [Related]
19. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
20. bcr gene rearrangement analysis in myeloproliferative disorders other than chronic myelogenous leukemia.
Crisan D; Mattson JC; O'Malley BA; Schulz RW; Wilner F
Cancer Detect Prev; 1996; 20(4):263-9. PubMed ID: 8818385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
